RA Williams sets new standards for epilepsy treatment with Iracet

RA Williams Distributors Limited is revolutionising epilepsy care in Jamaica with the introduction of Iracet, the first generic Levetiracetam available in Jamaica. Iracet, a play on the drug name LevetIRACETam, provides an affordable alternative to the costly brand-name version, making epilepsy treatment more accessible.

Essential for managing seizures, Levetiracetam is FDA-approved but often financially out of reach for many Jamaicans. Manufactured by Square Pharmaceuticals, a global leader in high-quality, affordable medications, Iracet delivers a safe and effective solution for treating epilepsy, including post-stroke seizures.

With an excellent safety profile, especially for women who are pregnant or planning to conceive, Iracet offers a safe and affordable treatment option for those who have struggled to access effective epilepsy care. Now covered by all major health insurance schemes, including the National Health Fund (NHF), Iracet’s availability makes it an accessible solution for patients across Jamaica, improving quality of life and providing a reliable option for managing their condition.

Speaking at the launch event held on November 24, Dr Ernestine Watson, chairperson of the Pharmacy Council of Jamaica, endorsed the life-changing treatment during her keynote address. “Iracet is not metabolised in the liver, meaning it won’t interact with other medications the patient may be taking, thus avoiding dangerous complications. Unlike some other anti-epileptic drugs, Iracet doesn’t cause side effects like changes in facial shape, gum thickening, serious rashes, excessive nausea, or bleeding,” Dr Watson said.

“It can be used in a wide range of scenarios, from childhood epilepsy to older patients, and even as an adjunct therapy for those who need additional support,” she added.

The event brought together healthcare professionals, government representatives, and advocates, underscoring the collective commitment to championing healthcare innovation and raising awareness about epilepsy.

“Iracet stands out for its unique safety profile, which includes a low potential for drug-drug interactions, making it an excellent option for patients with complex health conditions, such as those on anti-coagulants, statins, or oral contraceptives,” said Tamara Melville-Scott, country manager at Square Pharmaceuticals.

“Most importantly, it is safe for pregnant patients and women of reproductive age, offering both practitioners and patients peace of mind when managing epilepsy treatment,” she added.

Dionne Gayle, assistant chief education officer at the Ministry of Education, also delivered a compelling address, discussing the impact of epilepsy on school-aged children. “Epilepsy can present significant challenges for school-age children. Seizures, particularly if frequent or severe, can disrupt a child’s learning and social interactions, leading to anxiety, stigma, and feelings of isolation. The availability of affordable, effective medication, like Iracet, is not only a breakthrough for the health of these children but also for their ability to succeed academically, socially, and emotionally,” Gayle said.

As the exclusive distributor of Iracet in Jamaica, RA Williams continues its commitment to providing high-quality healthcare solutions to the Jamaican people. The company, with over 12 years of experience in the industry, partnered with Square Pharmaceuticals to introduce this groundbreaking treatment.

“For the past decade, this partnership with Square Pharmaceuticals has been built on a shared commitment to improving the lives of those we serve. The introduction of Iracet is more than just a product introduction. It is a celebration of progress, accessibility, and hope for countless Jamaicans affected by epilepsy,” said Audley Reid, CEO of RA Williams Distributors.

“By making this medication affordable, we are addressing critical health issues while equipping families with the tools they need to improve their quality of life,” she added.

RA Williams’ role in introducing Iracet reinforces the company’s reputation as a leader in healthcare distribution, ensuring that patients in Jamaica have access to the latest advancements in medical treatment.